Is AbbVie a Millionaire Maker?
(NYSE: ABBV) is an investment that is full of contradictions. It has a strong pharmaceutical business, but the third quarter of 2025 was terrible on the earnings front. It has an attractive 3% dividend yield, but it is near the low side of the historical yield range. Given the pros and cons, could buying AbbVie now help you build a million-dollar portfolio?
AbbVie is a pharmaceutical company. With a market cap of $400 billion, it is a substantial competitor in the industry. Its core focus is on immunology, oncology, neuroscience, and aesthetics. You may be familiar with some of its well-known brand-name drugs, including Humira and Botox. There's an interesting dichotomy here.
Image source: Getty Images.
Source Fool.com
AbbVie Inc. Stock
€191.40
1.810%
With 35 Buy predictions and not a single Sell prediction AbbVie Inc. is an absolute favorite of our community.
With a target price of 209 € there is a slightly positive potential of 9.2% for AbbVie Inc. compared to the current price of 191.4 €.
